Ranking · Winter 2024 · Healthcare · Therapeutics

Eris Biotech

Our drugs engage the immune system to fight tumors

5.3%

odds of being acquired in the next two years

0.8× the average (6.8%)

#3246 of 4,339 active YC companies · top 76%

Team of 2 · Lehi, UT, USA

Raises the odds

↑ 1.5–3 years since YC

↑ based in United States of America

↑ based in America / Canada

Lowers the odds

↓ team of 1–2

↓ industry: Healthcare

↓ tag: Biotech

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads Eris Biotech's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

erisbio.com YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub